Trial site
Novo-Med Zielinski I Wspolnicy Sp. j.
- 13running trials
- 8closed trials
The trials here
What the 22 trials at this site are about, from their registry records.
- Conditions
- Epilepsy8 trials
- Multiple sclerosis6 trials
- Alzheimer disease3 trials
- Myasthenia gravis3 trials
- Migraine1 trial
- Mild cognitive impairment1 trial
- Parkinson disease1 trial
- Phase
- Phase 313 trials
- Phase 26 trials
- Phase 2/32 trials
- Phase 1/21 trial
- Status
- Recruiting8 trials
- Completed7 trials
- Active, not recruiting5 trials
- Suspended1 trial
- Terminated1 trial
- Lead sponsor
- Biogen4 trials
- Xenon Pharmaceuticals Inc.3 trials
- Biohaven Therapeutics Ltd.2 trials
- Praxis Precision Medicines Inc.2 trials
- Zenas BioPharma (USA), LLC2 trials
- and 9 more
Running trials
Recruiting
SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures
Recruiting
Recruiting
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Recruiting
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Recruiting
Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy.
Active, not recruiting
Enrolling by invitation
Active, not recruiting
Enrolling by invitation
Recruiting
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Epilepsy5 recruiting
- Multiple sclerosis2 recruiting
- Myasthenia gravis1 recruiting
Closed trials
Active, not recruiting
Completed
Completed
Completed
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
Completed
GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)
Completed
Terminated
Completed
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
Site data: EU CTIS (euclinicaltrials.eu)Updated 18 Nov 2026